FDA Approves J&J's Rybrevant for EGFR-Mutated NSCLC, Third New Indication in 2024

Sep 19, 2024, 10:21 PM

The U.S. Food and Drug Administration (FDA) has approved Rybrevant (amivantamab-vmjw) in combination with standard care for the treatment of EGFR-mutated advanced non-small cell lung cancer (NSCLC). This approval marks the first targeted regimen to significantly reduce the risk of disease progression by more than half in the second-line setting and is the third new indication for Johnson & Johnson (J&J) in 2024. This development is part of a broader trend of advancements in lung cancer treatment, highlighted at the 2024 IASLC World Conference on Lung Cancer (WCLC24).